Answer
Post-marketing reports with Omjjara (momelotinib) include rash requiring hospitalisation, including erythema multiforme and one case of toxic epidermal necrolysis (TEN).
Sources for this answer
- Omjjara 150 mg film-coated tabletsGlaxoSmithKline UK · emc · SmPC §4.8 Undesirable effects · Version 4Document updated
Sources checked